Rebranded Servier eyes €3bn in cancer drug sales by 2030
pharmaphorum
OCTOBER 6, 2022
Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category. The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4
Let's personalize your content